Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15529727 | 0.80 | USP2 (0.50) | USP2TSHRLMNAKDM4EALDH1A1 | |
| SCHEMBL11581155 | 0.80 | USP2 (0.50) | USP2TSHRLMNAKDM4EALDH1A1 | |
| SCHEMBL7681690 | 0.80 | TSHR (0.50) | USP2TSHRLMNAKDM4EALDH1A1 | |
| SCHEMBL164302 | 0.78 | USP2 (0.60) | USP2TSHRLMNAKDM4EALDH1A1 | |
| Ethane Dimethane Sulfonate SCHEMBL1336145 | 0.76 | USP2 (0.75) | USP2TSHRLMNAKDM4EALDH1A1 | |
| SCHEMBL8339214 | 0.76 | LMNA (0.40) | LMNAKDM4EALDH1A1CA1CA2 | |
| SCHEMBL5900952 | 0.76 | USP2 (0.57) | USP2TSHRLMNAKDM4EALDH1A1 | |
| SCHEMBL565251 | 0.76 | USP2 (0.57) | USP2TSHRLMNAKDM4EALDH1A1 | |
| Methylamine SCHEMBL6472047 | 0.75 | LMNA (0.36) | LMNACA1CA2CA9 | |
| SCHEMBL15530094 | 0.75 | LMNA (0.50) | USP2TSHRLMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683077-B2 | Piperidine derivative | AJINOMOTO CO., INC. (JP) | 2010-03-23 | — | — | US | disclosed |
| EP-1951234-A2 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007048088-A2 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-26 | — | — | WO | disclosed |
| US-20070021460-A1 | Novel piperidine derivative | AJINOMOTO CO., INC. (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20070021460-A1 | Novel piperidine derivative | AJINOMOTO CO., INC. (JP) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021460-A1 | Novel piperidine derivative | HTR7, TPH1, HTR5A | USP2 2150/4885TSHR 3421/4885LMNA 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.